Might get a fomo pop that high upon FDA IDE approval, if enough confuse that with FDA approval, but it would be just that, a very short pop. Sustained price ~$10/share? Likely nothing less than FDA approval. But a pop price might go much higher than that on post FDA approval buyout speculation. On other side of coin, don't think price would get near that high on a buyout based on positive human data alone before FDA approval. In any case, my focus at moment is much nearer term IDE approval cuz everything else is moot if that doesn't happen.
News 
Market Data 
Discover 
